Immunotherapy in patients with early stage resectable nonsmall cell lung cancer

Minimally invasive testing for early detection of lung cancer to improve patient survival is a major unmet clinical need. This study aimed to develop and validate a serum multi-microRNA (multimiR) panel as a minimally invasive test for early detection of nonsmall cell lung cancer (NSCLC) regardless of smoking status, gender, and ethnicity. Our study included 744 NSCLC cases and 944 matched controls, including smokers and nonsmokers, male and female, with Asian and Caucasian subjects. Using RT-qPCR and a tightly controlled workflow, we quantified the absolute expression of 520 circulating microRNAs (miRNAs) in a Chinese cohort of 180 early stage NSCLC cases and 216 healthy controls (male smokers). Candidate biomarkers were verified in two case-control cohorts of 432 Chinese and 218 Caucasians, respectively (including females and nonsmokers). A multimiR panel for NSCLC detection was developed using a twofold cross-validation and validated in three additional Asian cohorts comprising 642 subjects. We discovered 35 candidate miRNA biomarkers, verified 22 of them, and developed a five-miR panel that detected NSCLC with area under curve (AUC) of 0.936–0.984 in the discovery and verification cohorts. The panel was validated in three independent cohorts with AUCs of 0.973, 0.916, and 0.917. The sensitivity of five-miR test was 81.3% for all stages, 82.9% for stages I and II, and 83.0% for stage I NSCLC, when the specificity is at 90.7%. We developed a minimally invasive five-miR serum test for detecting early stage NSCLC and validated its performance in multiple patient cohorts independent of smoking status, gender, and ethnicity.

Download Full-text

Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer

Genes Chromosomes and Cancer ◽

10.1002/gcc.20902 ◽

2011 ◽

Vol 50 (10) ◽

pp. 812-822 ◽

Cited By ~ 83

Author(s):

Urmo Võsa ◽

Tõnu Vooder ◽

Raivo Kolde ◽

Krista Fischer ◽

Kristjan Välk ◽

...

Keyword(s):

Lung Cancer ◽

Prognostic Marker ◽

Cell Lung Cancer ◽

Early Stage ◽

Nonsmall Cell Lung Cancer

Download Full-text

Radiofrequency Ablation for Early-Stage Nonsmall Cell Lung Cancer

BioMed Research International ◽

10.1155/2014/152087 ◽

2014 ◽

Vol 2014 ◽

pp. 1-11 ◽

Cited By ~ 22

Author(s):

Takao Hiraki ◽

Hideo Gobara ◽

Toshihiro Iguchi ◽

Hiroyasu Fujiwara ◽

Yusuke Matsui ◽

...

Keyword(s):

Lung Cancer ◽

Radiofrequency Ablation ◽

Cell Lung Cancer ◽

Early Stage ◽

Survival Rates ◽

Nonsmall Cell Lung Cancer ◽

Stage I ◽

Sublobar Resection ◽

Early Stage Nsclc ◽

Local Progression

This review examines studies of radiofrequency ablation (RFA) of nonsmall cell lung cancer (NSCLC) and discusses the role of RFA in treatment of early-stage NSCLC. RFA is usually performed under local anesthesia with computed tomography guidance. RFA-associated mortality, while being rare, can result from pulmonary events. RFA causes pneumothorax in up to 63% of cases, although pneumothorax requiring chest drainage occurs in less than 15% of procedures. Other severe complications are rare. After RFA of stage I NSCLC, 31–42% of patients show local progression. The 1-, 2-, 3-, and 5-year overall survival rates after RFA of stage I NSCLC were 78% to 100%, 53% to 86%, 36% to 88%, and 25% to 61%, respectively. The median survival time ranged from 29 to 67 months. The 1-, 2-, and 3-year cancer-specific survival rates after RFA of stage I NSCLC were 89% to 100%, 92% to 93%, and 59% to 88%, respectively. RFA has a higher local failure rate than sublobar resection and stereotactic body radiation therapy (SBRT). Therefore, RFA may currently be reserved for early-stage NSCLC patients who are unfit for sublobar resection or SBRT. Various technologies are being developed to improve clinical outcomes of RFA for early-stage NSCLC.

Download Full-text